A Clinical Study of Tranilast in the Treatment of Sarcoidosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03528070|
Recruitment Status : Not yet recruiting
First Posted : May 17, 2018
Last Update Posted : May 17, 2018
|Condition or disease||Intervention/treatment||Phase|
|Sarcoidosis||Drug: Tranilast||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||56 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Clinical Study of Tranilast in the Treatment of Sarcoidosis|
|Estimated Study Start Date :||May 2018|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||December 2020|
Subjects will be treated with tranilast
- Changes in the size of the pulmonary nodule by ultrasound [ Time Frame: 12 months ]During tranilast (0.1g each time, three times a day,12 months) treatment, patients need to retest the size of the pulmonary nodule by ultrasound. The investigators can get the changes in the size of the pulmonary nodule.
- Changes of the forced vital capacity(FVC) [ Time Frame: 12 months ]During tranilast (0.1g each time, three times a day,12 months) treatment, patients need to retest the forced vital capacity(FVC),then get the changes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03528070
|Contact: Maihua Hou, professor||+86 firstname.lastname@example.org|